.jpg)
Image Credit: Scientific Frontline / stock image
Scientific Frontline: Extended "At a Glance" Summary
The Core Concept: A shift in cancer treatment strategy where immunotherapy is administered at earlier stages of the disease—specifically before or after surgery—rather than being reserved solely for advanced, inoperable cases.
Key Distinction/Mechanism: The approach utilizes neoadjuvant treatment (given before surgery) to help the immune system better recognize tumor cells while the tumor is still present, and adjuvant treatment (given after surgery) to reduce the risk of the disease returning. This differs from the traditional use of immunotherapy as a last-line defense for metastatic cancer.
Origin/History: The comprehensive review highlighting this shift was published in the Journal of Internal Medicine in February 2026 by researchers at the Karolinska Institutet.
Major Frameworks/Components:
- Neoadjuvant Therapy: Pre-surgical administration intended to prime the immune response against the visible tumor.
- Adjuvant Therapy: Post-surgical administration aimed at eliminating residual microscopic disease.
- Targeted Tumor Areas: The review synthesizes findings across seven specific cancer types: skin, lung, breast, gastrointestinal, gynecological, head and neck, and urological cancers.


.jpg)
.jpg)





_MoreDetail-v3_x2_730x524.jpg)




